WEDNESDAY, Sept. 7, 2022 (HealthDay News) — Patients suspected of experiencing amyotrophic lateral sclerosis (ALS) may soon be capable of geting a diagnosis a lot more quickly, not wasting the time many have gone, new research suggests.
In 2020, a blood test for ALS predicated on microRNA (short segments of genetic material) originated by scientists from the business Brain Chemistry Labs, nonetheless it required precise protocols for shipping and storage of blood samples, that have been maintained at 80 Celsius. That meant many doctors and neurologists couldnt utilize the test.
Now, researchers from the business, Dartmouth’s department of neurology and the U.S. Centers for Disease Control and Prevention report they are in a position to replicate the initial test with blood samples which were not collected and maintained under such stringent requirements.
They did so by comparing blinded blood samples from 50 ALS patients from the U.S. National ALS Biorepository with 50 healthy “control” participants. The investigators discovered that in this new test the genetic fingerprint of five microRNA sequences accurately discriminated between people who have ALS and healthy individuals.
We were surprised that the microRNA test worked for samples collected from the selection of investigators under differing conditions, said first author Dr. Sandra Banack.
The doctors are actually verifying the brand new blood test, and Brain Chemistry Labs, in Wyoming, has requested a patent on the test, in accordance with an organization news release.
ALS, also referred to as Lou Gehrig’s disease, can be an incurable neurological disease. Currently, the lag time taken between when symptoms begin and diagnosis is given has ended per year. An inaccurate diagnosis may appear in about 13% to 68% of cases. Unfortunately, most ALS patients die between two to five years after diagnosis.
The findings were published online Aug. 29 in the Journal of the Neurological Sciences .
The U.S. National Institute of Neurological Disorders and Stroke has more on ALS.
SOURCE: Brain Chemistry Labs, news release, Aug. 31, 2022